Evidence map›Paper›PMID 33170774›Full record

ArticleeLife2020

Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser.

Keerthana Gnanapradeepan, Julia I-Ju Leu, Subhasree Basu, Thibaut Barnoud, Madeline Good, Joyce V Lee, William J Quinn, Che-Pei Kung, Rexford Ahima, Joseph A Baur and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Emerging insights into ethnic-specific TP53 germline variants.Journal of the National Cancer Institute · 2023
    Review
  3. The African-centric P47S Variant ofCancer research communications · 2023
    Article
  4. Association ofBiomedicines · 2023
    Article
  5. Common activities and predictive gene signature identified for genetic hypomorphs ofProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Keerthana GnanapradeepanProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.ORCID 0000-0002-8984-9742
Julia I-Ju LeuDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Subhasree BasuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.
Thibaut BarnoudProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.ORCID 0000-0001-5588-6281
Madeline GoodProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.
Joyce V LeeDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
William J QuinnDepartment of Physiology and Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Che-Pei KungWashington University in St. Louis, St Louis, United States.ORCID 0000-0002-1150-4998
Rexford AhimaDivision of Endocrinology, Diabetes & Metabolism, Johns Hopkins University School of Medicine, Baltimore, United States.
Joseph A BaurDepartment of Physiology and Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0001-8262-6549
Kathryn E WellenDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.ORCID 0000-0002-2281-0042
Qin LiuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.
Zachary T SchugProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.
Donna L GeorgeDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
Maureen E MurphyProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, United States.ORCID 0000-0001-7644-7296
The Wistar Institute · USUniversity of Pennsylvania · USJohns Hopkins University · USWashington University in St. Louis · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL A. LAZAR · 1986 to 2026
$48.3M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F, WEERARATNA, ASHANI T · 2008 to 2023
$37.1M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
ONCOLOGY: CHEMOTHERAPY, IMMUNOLOGY, BIOLOGYT32CA009071 · NCI · JOHNS HOPKINS UNIVERSITY · PI Mary Y Armanios, Nilofer S. Azad · 1985 to 2026
$12.8M
Functional Analysis of p53 Polymorphic Variants - Diversity SupplementR01CA102184 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 2005 to 2026
$7.4M
Targeting NAD Metabolism to Improve Glucose Homeostasis in Obesity and AgingR01DK098656 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Joseph A. Baur · 2013 to 2026
$6.1M
The ARF Tumor SuppressorR01CA139319 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2010 to 2019
$3.9M
Role of acetyl-CoA in linking cancer cell metabolism and epigeneticsR01CA174761 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WELLEN, KATHRYN ELAINE · 2014 to 2024
$3.6M
The impact of coding region variants on mutant p53 biologyR01CA238611 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2020 to 2024
$2.2M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Molecular Mechanisms of Rapamycin's Effects on Health and LongevityR01AG043483 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BAUR, JOSEPH A. · 2013 to 2017
$2.0M
NCI NIH HHS CA238611NCI NIH HHS Cancer Center Support Grant (CCSG) P30 CA010815NCI NIH HHS DP2-CA249951NCI NIH HHS F32 CA220972NCI NIH HHS K99 CA241367NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA102184NCI NIH HHS R01 CA139319NCI NIH HHS R01 CA174761NCI NIH HHS R01 CA238611NCI NIH HHS R50 CA221838NCI NIH HHS T32 CA009071NCI NIH HHS T32 CA009171NIA NIH HHS R01 AG043483NIDDK NIH HHS P30 DK019525NIDDK NIH HHS P30 DK19525NIDDK NIH HHS R01 DK098656NIH HHS S10 OD023586NIH HHS S10 OD023658
6 · The paper itself

Abstract

The Pro47Ser variant of p53 (S47) exists in African-descent populations and is associated with increased cancer risk in humans and mice. Due to impaired repression of the cystine importer

Indexed as

Amino Acid SubstitutionAnimalsBlack PeopleCell LineGlutathioneGlycolysisHumansMitochondriaOxidation-ReductionTOR Serine-Threonine KinasesTumor Suppressor Protein p53GlutathioneMTOR protein, humanmTOR protein, mouseTOR Serine-Threonine KinasesTumor Suppressor Protein p53cancer biologyGAPDHhumanmetabolismmousemTORp53Pro47SerRheb

Identifiers

PMID33170774
PMCPMC7661039
OpenAlexW3105981667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.